In the 30-patient study conducted at the Children’s Hospital of Philadelphia and the Hospital of the University of Pennsylvania using tisagenlecleucel, CRS was experienced by 100% of the patients, with 27% of cases being severe (grade 3 or higher); however, the investigators noted that the C-reactive protein (CRP) functioned as a reliable indicator for CRS severity and allowed for successful abatement with tocilizumab [58,59]. This evidence concerns the gene CRP and congenital rubella syndrome.